Inhibition of Receptor-Interacting Protein Kinase 1 in Chronic Plaque Psoriasis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

ConclusionAdministration of the RIPK1 inhibitor GSK2982772 to patients with moderate to severe plaque psoriasis did not translate into meaningful clinical improvements.

http://link.springer.com/10.1007/s13555-024-01097-0

Source: Dermatology and Therapy - February 19, 2024 Category: Dermatology Source Type: research